Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Half of people with worse liver function responded well to immunotherapy.
Physicians recognize that ovarian cancer isn’t a single disease but a group of related disorders with distinct genetic and cellular features
Whether such recurrence is less likely after interferon treatment remains the source of some controversy in the hep C research community.
Liver fat may be a driver of increased cancer risk associated with obesity.
A second immunotherapy option is now available for hepatocellular carcinoma.
Venclexta plus Gazyva reduces risk of disease progression or death.
Investigators have found biomarkers that might one day be used to help detect liver cancer during earlier stages.
Mayo Clinic study finds sparing the hippocampus leads to better outcomes.
Lorlatinib shrinks tumors in half of patients previously treated with older ALK inhibitors.
Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.
Mutation revelation is a boon in an era of targeted therapies, say oncologists at UCSF, Children’s National Health System.
Bavencio or Keytruda plus targeted therapy slowed disease progression in Phase III studies.
Mouse study shows how transplanting patients’ own healthy blood stem cells can curb cancer, opening door to better treatments.
Rubraca shrank tumors and lowered PSA levels in men with advanced prostate cancer.
In particular, women have a higher risk of cervical cancer and men have a higher risk of anal cancer.
Tecentriq plus chemotherapy delays disease progression or death in people with metastatic triple-negative breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.